PREVECEUTICAL MEDICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.025 CAD | 0.00% |
|
+25.00% | 0.00% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 23.08 | 19.51 | 5.947 | 14.76 | 12.79 | 13.38 |
| Enterprise Value (EV) 1 | 25.7 | 23.1 | 10.67 | 17.62 | 15.71 | 16.67 |
| P/E ratio | -2.91 x | -1.34 x | -1.66 x | -3.6 x | -7.36 x | -8.81 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1,038 x | 1,263 x | 1,962 x | - | - | - |
| EV / Revenue | 1,156 x | 1,495 x | 3,519 x | - | - | - |
| EV / EBITDA | -5.81 x | -3.35 x | -3.13 x | -8.47 x | -18.9 x | -16.2 x |
| EV / FCF | -59.6 x | -70.8 x | -12.9 x | -1,140 x | -53.9 x | -67.8 x |
| FCF Yield | -1.68% | -1.41% | -7.77% | -0.09% | -1.86% | -1.48% |
| Price to Book | -67 x | -8.54 x | -1.33 x | -4.1 x | -3.12 x | -2.89 x |
| Nbr of stocks (in thousands) | 245,523 | 390,189 | 396,449 | 492,149 | 511,703 | 535,303 |
| Reference price 2 | 0.0940 | 0.0500 | 0.0150 | 0.0300 | 0.0250 | 0.0250 |
| Announcement Date | 4/24/18 | 4/18/19 | 4/29/20 | 4/13/21 | 5/2/22 | 5/1/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.0222 | 0.0155 | 0.003031 | - | - | - |
| EBITDA 1 | -4.425 | -6.887 | -3.408 | -2.079 | -0.8298 | -1.026 |
| EBIT 1 | -4.442 | -6.923 | -3.436 | -2.093 | -0.8349 | -1.036 |
| Operating Margin | -19,978.8% | -44,802.96% | -113,356.09% | - | - | - |
| Earnings before Tax (EBT) 1 | -7.329 | -11.92 | -3.587 | -3.807 | -1.747 | -1.481 |
| Net income 1 | -7.232 | -11.88 | -3.579 | -3.801 | -1.727 | -1.481 |
| Net margin | -32,526.24% | -76,909.98% | -118,076.54% | - | - | - |
| EPS 2 | -0.0323 | -0.0373 | -0.009043 | -0.008341 | -0.003399 | -0.002839 |
| Free Cash Flow 1 | -0.4313 | -0.3264 | -0.8289 | -0.0155 | -0.2916 | -0.246 |
| FCF margin | -1,939.97% | -2,112.59% | -27,348.93% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/24/18 | 4/18/19 | 4/29/20 | 4/13/21 | 5/2/22 | 5/1/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 2.62 | 3.59 | 4.72 | 2.86 | 2.91 | 3.29 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.5929 x | -0.5209 x | -1.385 x | -1.374 x | -3.511 x | -3.203 x |
| Free Cash Flow 1 | -0.43 | -0.33 | -0.83 | -0.02 | -0.29 | -0.25 |
| ROE (net income / shareholders' equity) | 2,259% | 904% | 106% | 94% | 44.8% | 33.9% |
| ROA (Net income/ Total Assets) | -198% | -192% | -156% | -226% | -225% | -370% |
| Assets 1 | 3.656 | 6.182 | 2.3 | 1.685 | 0.767 | 0.4008 |
| Book Value Per Share 2 | -0 | -0.0100 | -0.0100 | -0.0100 | -0.0100 | -0.0100 |
| Cash Flow per Share 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capex 1 | 0.17 | 0.01 | - | - | - | - |
| Capex / Sales | 746.93% | 49.63% | - | - | - | - |
| Announcement Date | 4/24/18 | 4/18/19 | 4/29/20 | 4/13/21 | 5/2/22 | 5/1/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 9.78M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PREV Stock
- Financials PreveCeutical Medical Inc.
